Librexia Program - Stroke Prevention in Atrial Fibrillation

Our Phase 3 Librexia program, the most comprehensive FXIa inhibitor clinical development program today, is evaluating patients in three studies - event reduction in acute coronary syndromes, stroke prevention in atrial fibrillation, and stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack. Through our ongoing efforts, we aim to address unmet needs for the millions of patients impacted by stroke and cardiovascular diseases worldwide.
“We've made tremendous advances in understanding atrial fibrillation and also treating atrial fibrillation over the last couple of decades. However, right now, many patients are not being treated as adequately as they need to be.” - Dr. Mahaffey